The responses show that all countries follow guidelines regarding EGFR and ALK testing, with most countries testing only advanced stages of adenocarcinomas, NSCLC-NOS, and NSCLC when an adenocarcinoma component cannot be excluded. This evidence concerns the gene EGFR and non-small cell lung carcinoma.